



McKesson Corporation (MCK)

Updated June 4th, 2020 by Josh Arnold

Key Metrics

Current Price:	\$162	5 Year CAGR Estimate:	8.3%	Market Cap:	\$26.2 B
Fair Value Price:	\$173	5 Year Growth Estimate:	6.0%	Ex-Dividend Date:	08/29/20 ¹
% Fair Value:	94%	5 Year Valuation Multiple Estimate:	1.3%	Dividend Payment Date:	10/01/20 ²
Dividend Yield:	1.0%	5 Year Price Target	\$231	Years Of Dividend Growth:	12
Dividend Risk Score:	A	Retirement Suitability Score:	C	Last Dividend Increase:	5.1%

Overview & Current Events

McKesson Corporation traces its lineage to 1833 when its founders began to offer wholesale chemicals and pharmaceuticals in New York City. In the 187 years since, McKesson has grown into a powerhouse in the pharmaceutical and medical distribution industry and today, generates nearly \$236 billion in annual revenue and trades with a \$26 billion market capitalization.

McKesson reported fourth quarter and full-year earnings on May 20th, with results beating expectations on the top and bottom lines. Revenue was up 12% year-over-year in the fourth quarter, rising to \$58.5 billion. Full-year revenue was up 8% to \$231 billion, driven by growth in the US Pharmaceutical and Specialty Solutions segment. Branded pharmaceutical price increases and higher volumes from retail national accounts drove the top line higher.

Earnings on an adjusted basis were \$4.27 in Q4, up 16% from \$3.69 in the year-ago period, primarily driven by a lower share count and growth in the European Pharmaceutical Solutions segment. Full-year adjusted earnings-per-share were \$14.95, up from \$13.57 in the prior year. The 10% gain was due to a lower share count, as well as strong growth in the US Pharmaceutical and Specialty Solutions and Medical Surgical segments, respectively, partially offset by higher corporate expenses.

Capital returns were \$2.2 billion for the full year, with \$1.9 billion of that coming in the form of share repurchases. Free cash flow for the year was very strong at \$3.9 billion.

McKesson expects full-year earnings of \$13.95 to \$14.75 per share, which reflects anticipated headwinds due to COVID-19. We're out with an initial estimate of \$14.40.

Growth on a Per-Share Basis

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2026
EPS	\$5.00	\$5.83	\$6.33	\$8.35	\$11.11	\$9.84	\$11.61	\$12.62	\$13.57	\$14.95	\$14.40	\$19.27
DPS	\$0.72	\$0.80	\$0.80	\$0.92	\$0.96	\$1.08	\$1.12	\$1.30	\$1.51	\$1.62	\$1.64	\$2.30
Shares³	252	235	227	231	232	225	211	202	191	173	173	155

McKesson's earnings-per-share history is quite robust, having grown nearly every year in the past decade. Indeed, McKesson has managed to average more than 10% earnings-per-share growth annually over this time frame through organic revenue growth and many acquisitions. We do not believe that sort of growth is likely for the longer term as McKesson has grown much larger. As a result, it seems to have neared a plateau on operating margins and revenue growth, but we do still see 6% annual earnings-per-share growth as sustainable moving forward.

McKesson can achieve this result largely via revenue gains, which we forecast will be in the area of 3% for the foreseeable future. It continues to acquire growth in bolt-on acquisitions with companies that supplement its current offerings, a strategy that is unlikely to change. Margins have been flat for some time, so we expect that will continue.

¹ Estimated date

² Estimated date

³ Share count in millions

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



McKesson Corporation (MCK)

Updated June 4th, 2020 by Josh Arnold

The buyback should continue to meaningfully reduce the float over time, which we see as a key driver of earnings-per-share growth. We remain somewhat cautious due to an increasingly hostile regulatory environment for drug wholesalers like McKesson. In addition, constant pressure on pricing from regulators, as well as strong generic conversion are headwinds. However, recent results have been quite supportive of long-term growth.

The dividend has never been a priority for McKesson and that is not likely to change anytime soon. We see the payout rising from today's \$1.64 to \$2.30 in five years, but the dividend remains just a small fraction of earnings.

Valuation Analysis

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	Now	2026
Avg. P/E	13.6	13.8	14.9	16.8	17.9	20.1	14.1	12.0	9.7	9.3	11.2	12.0
Avg. Yld.	1.1%	1.0%	0.8%	0.7%	0.5%	0.5%	0.7%	0.5%	1.1%	1.2%	1.0%	1.0%

The stock's price-to-earnings ratio has ebbed and flowed in the past decade but today, at 11.2 times earnings, it appears slightly undervalued relative to its historical norm. We see fair value as 12 times earnings and thus, McKesson offers a reasonable value to prospective shareholders in our view. This could provide a very small tailwind to total returns over the next five years if the stock's valuation reverts to more normalized levels. The yield should remain about where it is for the foreseeable future.

Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2026
Payout	13%	13%	13%	11%	9%	11%	10%	10%	11%	11%	11%	12%


The payout ratio will remain very low barring a material strategic shift, which we are not forecasting. Instead, McKesson will almost certainly continue to boost earnings-per-share by reducing the float, as it did once again in fiscal 2020.

Its competitive advantage is in its willingness to adapt and shift to the changing needs of its customers, its willingness to buy growth and its immense scale, which affords purchasing power. McKesson should hold up well during this recession given its product assortment that offers healthcare consumers things they need, and not discretionary items.

Final Thoughts & Recommendation

McKesson continues to look attractive as it offers a decent growth outlook, a robust share repurchase program and a valuation that is still under our view of fair value. We are forecasting 8.3% annual total returns going forward, consisting of the current 1% yield, 6% earnings-per-share growth and a small tailwind from a rising valuation. That would make McKesson attractive for investors seeking growth or value, but its low yield would make it unattractive for investors seeking high levels of income. Due to the higher valuation, we're reiterating McKesson at a hold rating.

Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



McKesson Corporation (MCK)

Updated June 4th, 2020 by Josh Arnold

Income Statement Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Revenue (\$B)	112.1	122.3	122.2	137.4	179.0	190.9	198.5	208.4	214.3	231.1
Gross Profit	5,970	6,402	6,881	8,352	11,411	11,416	11,271	11,184	11,754	12,023
Gross Margin	5.3%	5.2%	5.6%	6.1%	6.4%	6.0%	5.7%	5.4%	5.5%	5.2%
SG&A Exp.	3,529	3,727	4,110	5,388	7,901	7,379	7,447	8,138	8,403	9,168
D&A Exp.	496	493	581	735	1,017	885	910	951	949	922
Operating Profit	2,034	2,273	2,338	2,507	3,118	3,645	3,483	2,921	3,280	2,759
Operating Margin	1.8%	1.9%	1.9%	1.8%	1.7%	1.9%	1.8%	1.4%	1.5%	1.2%
Net Profit	1,202	1,403	1,338	1,263	1,476	2,258	5,070	67	34	900
Net Margin	1.1%	1.1%	1.1%	0.9%	0.8%	1.2%	2.6%	0.0%	0.0%	0.4%
Free Cash Flow	1,950	2,552	2,083	2,717	2,567	2,995	4,182	3,765	3,479	3,868
Income Tax	505	514	587	757	815	908	1,614	(53)	356	18

Balance Sheet Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Total Assets	30,886	33,093	34,786	51,759	53,870	56,523	60,969	60,381	59,672	61,247
Cash & Equivalents	3,612	3,149	2,456	4,193	5,341	4,048	2,783	2,672	2,981	4,015
Acc. Receivable	7,982	8,562	8,683	12,169	13,117	14,519	14,602	14,349	14,941	17,201
Inventories	9,225	10,073	10,335	12,986	14,296	15,335	15,278	16,310	16,709	16,734
Goodwill & Int.	5,972	6,782	8,675	14,798	13,258	12,807	14,251	15,026	13,047	12,516
Total Liabilities	23,666	26,262	27,716	41,441	45,785	47,515	49,696	50,324	51,385	55,938
Accounts Payable	---	16,114	16,108	21,128	25,166	28,585	31,022	32,177	33,853	37,195
Long-Term Debt	4,004	3,980	4,873	10,594	9,844	8,114	8,545	7,880	7,595	7,387
Total Equity	7,220	6,831	7,070	8,522	8,001	8,924	11,095	9,804	8,094	5,092
D/E Ratio	0.55	0.58	0.69	1.24	1.23	0.91	0.77	0.80	0.94	1.45

Profitability & Per Share Metrics

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Return on Assets	4.1%	4.4%	3.9%	2.9%	2.8%	4.1%	8.6%	0.1%	0.1%	1.5%
Return on Equity	16.3%	20.0%	19.3%	16.2%	17.9%	26.7%	50.7%	0.6%	0.4%	13.7%
ROIC	11.4%	12.7%	11.8%	7.7%	7.6%	12.9%	27.4%	0.4%	0.2%	6.3%
Shares Out.	252	235	227	231	232	225	211	202	191	173
Revenue/Share	426.17	487.33	511.28	589.67	761.89	819.24	890.28	996.92	1,087.9	1,269.5
FCF/Share	7.41	10.17	8.72	11.66	10.92	12.85	18.75	18.01	17.66	21.25

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.